Cancer

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences…

2 months ago

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia At Global Health Exhibition 2025 held…

2 months ago

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia At Global Health Exhibition 2025 held…

2 months ago

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia At Global Health Exhibition 2025 held…

2 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record…

2 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record…

2 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record…

2 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion,…

2 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion,…

2 months ago

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

Initial Clinical Data Expected in the First Half of 2026SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion,…

2 months ago